Encephalopathy in a patient after long-term treatment with thalidomide

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4942-4944

  Sohlbach, Kristina ^a   Heinze, Stefan ^a   Shiratori, Kiyosh ^a   Sure, Ulrich ^a   Pagenstecher, Axel ^a   Neubauer, Andreas ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; THALIDOMIDE; VINCRISTINE; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LONG TERM CARE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SYMPTOMATOLOGY; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ANGIOGENESIS INHIBITORS; BRAIN DISEASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 33750621895     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.5920     Document Type: Article

References (14)

1. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
2. Haslett PA: Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25:53-57, 1998
3. McHugh SM, Rifkin IR, Deighton J, et al: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160-167, 1995
4. Keifer JA, Guttridge DC, Ashburner BP, et al: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387, 2001
5. Tosi P, Zamagni E, Cellini C, et al: Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 74:212-216, 2005
6. Offidani M, Corvatta L, Marconi M, et al: Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 72:403-409, 2004
7. Dimopoulos MA, Zervas K, Kouvatseas G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991-995, 2001
8. Moehler TM, Neben K, Benner A, et al: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98:3846-3848, 2001
9. Hovenga S, Daenen SM, de Wolf JT, et al: Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: A prospective phase II study. Ann Hematol 84:311-316, 2005
10. Cavaletti G, Beronio A, Reni L, et al: Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study. Neurology 22:2291-2293, 2004
11. Chaudhry V, Cornblath DR, Corse A, et al: Thalidomide-induced neuropathy. Neurology 59:1872-1875, 2002
12. Kennedy P: Viral encephalitis. J Neurol 252:268-272, 2005
13. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 65:89-98, 1981 (suppl 1)
14. Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 9:103-130, 1982